People
-
OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal… Read more . . .
-
Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time… Read more . . .
-
OINDP developer Nanopharm has announced the appointment of Mark Clement as non-executive Chairman of the Board. Clement has more than 25 years of experience in life sciences and is currently non-executive chairman or director of… Read more . . .
-
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company’s new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on… Read more . . .
-
Spyryx Biosciences, which is developing an inhaled peptide for the treatment of cystic fibrosis and other respiratory diseases, has announced the appointment of former Sunovion Head of Clinical Research Alistair Wheeler as Chief Medical Officer,… Read more . . .
-
Johnson & Johnson spinout PrEP Biopharm has announced that former GSK Global Head of Analytical Technologies Anna Slater has joined the company as Head of Chemistry, Manufacturing and Controls. At GSK, Slater had been a… Read more . . .
-
Spray-drying and DPI specialist Hovione announced the opening a new sales and customer support office in Osaka, Japan, saying that “The new office underlines the importance of Japan for Hovione’s business activities. Japan is a… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced the appointment of Lars Asking as VP as of May 1, 2016. Asking was most recently Principle Scientist at Novo Nordisk and previously developed inhaled products at… Read more . . .
-
InCarda Therapeutics, which is developing an inhaled treatment for paroxysmal atrial fibrillation, has appointed former Gilead Senior VP for Cardiovascular Therapeutics Luiz Belardinelli as Chief Medical Officer, the company said. Belardinelli will continue as a… Read more . . .
-
According to MannKind Corporation, the company’s net loss for 2015 was $368.4 million, and its cash and cash equivalents as of the end of 2015 totaled $59.1 million. The company also said that it has… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan